대한뉴팜

Daehan Nupharm recorded cumulative sales of KRW 151.2 billion and operating profit of KRW 14.9 billion for the third quarter of 2024.Net profit for the same period reached KRW 12.8 billion.
 

For the third quarter alone, the company posted sales of KRW 48.8 billion and operating profit of KRW 4.0 billion, continuing its strong financial performance.

This growth was largely driven by solid sales in its core pharmaceutical business and the successful launch of its new gastroesophageal reflux disease (GERD) treatment,"Rapiduo".

Rapiduo is the first and only combination therapy in Korea that pairs rabeprazole with magnesium oxide in a dual-core PPI formulation designed to improve quality of life for GERD patients.
The outer layer of magnesium oxide rapidly neutralizes gastric acid and increases pH levels, protecting the inner core of rabeprazole from acid degradation and enabling effective release in the stomach.
The product reaches peak plasma concentration within one hour and features reduced tablet size through dual-core technology, enhancing patient convenience.
 

To accelerate market penetration and strengthen product awareness, Daehan Nupharm has been actively organizing medical symposiums. The “Double Protection DUO” symposium series, held three times this month, focuses on Lapiduo’s clinical value. On October 20, a session will feature Professor Ji-Won Kim (Boramae Medical Center) as chair, with lectures by Professor Jung-Won Jeon (Kyung Hee University Hospital at Gangdong) and Dr. Joong-Won Yoon (Samsung Top Internal Medicine Clinic) covering topics such as “Pharmacotherapy for Peptic Ulcers” and “Best Practices for PPI Prescribing in Primary Care.”
 

In addition, the company continues to host its “Obesity & Wellness Injection Symposium” series, launched last year to share medical knowledge in the weight management and wellness field. Starting in Busan, followed by Seoul and Gyeongju, these events serve as key platforms to highlight Daehan Nupharm’s expertise and expand its presence in the market.